Comparable Analysis Pfizer

2588 Words11 Pages
Executive Summary In 2009, Pharmaceutical giant Pfizer, Inc. acquired Wyeth - a competitor within the industry - for $68B. This report offers a valuation of Wyeth at the time of purchase using two methods: the discounted free cash flow method and the comparable company method. The discounted free cash flow method yields a valuation of $84.73B while the comparable company method yields a valuation range of $57.56B to $73.39B. Part 1: Discounted Free Cash Flow to the Firm Valuation Methodology Discounted Free Cash Flow to Firm (DFCFF) analysis computes the fair value of the firm by taking the following steps: * Forecasting the income statement and balance sheet figures (see Appendices I and II for assumptions) * Preparing the Cash Flow Statement (see Appendix III) and computing Free Cash Flows to Firm (see Appendix V) for the forecasted years. * Determining the WACC and discounting the Free Cash Flow to Firm to obtain the Fair Value of Firm as on 1st July, 2009. * The Book Value of Outstanding debt is then deducted from the Fair Value of the Firm to calculate the Fair Value of Equity as of 1st July, 2009. Results Table 1 Forecasted Net Income and FCFF for Future Years Year | 2009E | 2010E | 2011E | 2012E | 2013E | 2014E | Net Income ($M) | $4,940 | $4,937 | $4,983 | $5,096 | $5,287 | $5,487 | FCFF | $4,674 | $4,937 | $5,019 | $5,141 | $5,347 | $5,559 | Determination of the Cost of Capital (WACC) In order to calculate the WACC, the value of Beta is first determined by performing a regression analysis on the historical returns of the Wyeth’s stock vs. the historical returns of entire NYSE market over the period of Jan 2004 through end June 2009. The appropriate Beta for Wyeth is determined to be 0.62. The Risk Free rate of return (6-Month T-Bill Rates 2009) is taken as an average of the annualized 6-month T-Bill rate over the

More about Comparable Analysis Pfizer

Open Document